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Abstract
Background—Prevalence of nonalcoholic fatty liver disease (NAFLD) and rate of advanced 
fibrosis among individuals with metabolic syndrome (MetS) and its individual metabolic 
abnormalities needs better understanding in the United States population. We aim to study these 
by using a large United States population database, the Third National Health and Nutrition 
Examination Survey (NHANES III).
Methods—A total of 11,674 individuals were included in our study cohort. NAFLD was defined 
as presence of moderate to severe hepatic steatosis on liver ultrasound in absence of viral hepatitis, 
significant alcohol use, elevated transferrin level and medication use leading to hepatic steatosis. 
Advanced fibrosis among those with NAFLD was determined using noninvasive method, the 
NAFLD Fibrosis Score. MetS was defined based on the National Cholesterol Education Program 
Adult Treatment Panel III definition.
Results—The prevalence of NAFLD among included study cohort was 18.2% (95% CI 16.5–
19.9). Individuals with metabolic abnormalities demonstrated higher prevalence (MetS: 43.2%, 
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increased waist circumference: 31.2%, impaired fasting glucose/diabetes: 41.2%, high triglyceride 
level: 34.7%, low HDL: 27.8%, high blood pressure: 29.2%). The individuals with MetS had 
significantly higher NAFLD prevalence compared to controls (aOR: 11.5, 95% CI 8.9–14.7). The 
severity of hepatic steatosis was also noted to increase with higher number of metabolic 
abnormalities. Among individual metabolic abnormalities, increased waist circumference, 
impaired fasting glucose/diabetes, high triglyceride and low HDL levels were found to be 
independently associated with NAFLD. Individuals with impaired fasting glucose/diabetes and 
those with five metabolic abnormalities had higher rate of advanced fibrosis (18.6% and 30.3% 
respectively). Prevalence of NAFLD among individuals without any metabolic abnormality was 
6.1%.
Conclusion—Prevalence of NAFLD and rate of advanced fibrosis are significantly high among 
individuals with metabolic abnormalities.
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BACKGROUND
Evidence of hepatic steatosis by imaging, in the absence of secondary causes of hepatic fat 
accumulation such as viral hepatitis, significant alcohol consumption, use of steatogenic 
medications, or hereditary disorders; suggests the presence of non-alcoholic fatty liver 
disease (NAFLD)1. The reported prevalence of NAFLD varies widely depending on the 
population studied and modality of diagnosis. The prevalence of NAFLD defined by 
ultrasound ranged from 17% to 46% worldwide. However, the prevalence of non-alcoholic 
steatohepatitis (NASH), a histological subtype of NAFLD, remains relatively lower than that 
of non-alcoholic fatty liver (NAFL). Studies regarding NASH related cirrhosis remains 
scarce and its prevalence not well studied1, 2.
Some of the common risk factors associated with the development of NAFLD include 
metabolic syndrome (MetS), obesity, diabetes, and dyslipidemia. The prevalence can exceed 
65% among individuals with metabolic abnormalities2. The exact mechanisms underlying 
the development of NAFLD in individuals with metabolic abnormalities remain unknown. 
Individuals with cryptogenic cirrhosis, now considered as “burned out NASH”, also exhibit 
significantly higher prevalence of type II diabetes mellitus, obesity, and dyslipidemia3, 4.
Most studies conducted in United States reported NAFLD prevalence rate of around 10% to 
35%. Previous studies have indicated higher prevalence among high risk groups but most of 
these studies suffered from small sample size2. Although imaging tests such as ultrasound 
do not accurately predict steatohepatitis in patients with NAFLD, its use in individuals with 
metabolic syndrome may be useful in identifying individuals who might benefit from 
diagnostic and prognostic liver biopsy, as metabolic syndrome is a strong predictor of 
steatohepatitis1, 5. Furthermore, ultrasonographic evidence of hepatic steatosis, combined 
with other non-invasive methods such as NAFLD Fibrosis Score6, improves diagnostic and 
prognostic yield. The aim of this study is to determine the prevalence of NAFLD defined by 
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ultrasonograohy, as well as the rate of advanced fibrosis using NAFLD Fibrosis Score, in the 
United States population stratified by different baseline metabolic abnormalities.
METHODS
The NHANES III was conducted in the United States from 1988 through 1994 by the 
National Center for Health Statistics, Centers for Disease Control and Prevention to obtain 
information regarding health and nutrition status of United States general population. It used 
complex, multistage, stratified, clustered samples of civilian from 2 months age and older. 
The survey included interviews questionnaires, standardized physical examination, and 
laboratory tests from blood samples collected at examination centers and analyzed at central 
laboratory. NHANES III was approved by the Center for Disease Control and Prevention’s 
Institutional Review board. Further information regarding survey design and sampling 
methods are available elsewhere7.
Study cohort
During the survey period, 33,199 subjects participated. In total, 16,115 subjects who were 
20–74 years old completed liver ultrasound examination. Only those liver ultrasound 
findings reported at ‘confident or absolute confident levels’ were included (N = 12,915). We 
excluded subjects with chronic hepatitis B, chronic hepatitis C, and excessive alcohol use or 
elevated transferrin level >50% (N=1642). In addition, those who were taking medications 
that might cause hepatic steatosis1, such as antiarrhythmic (amiodarone), antineoplastic - 
antimetabolites (methotrexate), antineoplastic – hormonal (tamoxifen), adrenal 
corticosteroids (corticosteroids), anticonvulsants (valproate), and antivirals (antiretroviral 
medicines) (N=113) were also excluded. The remaining 11,674 adults constituted our study 
cohort.
Variables and Definitions
Information on demographic characteristics, education and income level, cigarettes and 
alcohol use was obtained in a household interview. Smoking status was categorized into 
current and past users. Current smoker was defined as history of ongoing smoking with or 
without >100 cigarettes in lifetime. Excessive alcohol consumption was defined as an 
average >21 drinks per week in men and >14 drinks per week for women1. The average 
alcohol consumption was determined based on the two survey question responses that 
queried about the number of days of drinking and the number of drinks on a given drinking 
day over the past 12 months period.
During the physical examination, individual’s body weight, height, and waist to hip ratio 
were measured. The body mass index (BMI) was calculated and individuals with BMI ≥ 30 
kg/m2 were considered to be obese. Individuals with fasting plasma glucose of ≥126 mg/dl 
or random plasma glucose ≥ 200 mg/dl, use of oral hypoglycemic medications or insulin, 
and previous history of diabetes were considered to have diabetes8. The presence of 
metabolic syndrome (MetS) was defined based on the guidelines proposed by Third Report 
of the National Cholesterol Education Program Adult Treatment Panel (ATP III)9. The ATP 
III clinical definition of the MetS requires the presence of three or more of the following 
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abnormalities: (1) waist circumference > 102 cm in men and > 88 cm in women; (2) a 
triglyceride level ≥ 150 mg/dl; (3) HDL level < 40 mg/dl in men and < 50 mg/dl in women, 
(4) systolic blood pressure ≥ 130 mm Hg or diastolic pressure ≥ 85 mm Hg; and (5) fasting 
plasma glucose ≥ 110 mg/dl. Subjects with MetS were further trichotomized depending on 
the number of abnormalities of MetS components (three, four or five metabolic 
abnormalities). Elevated serum transaminases were defined as ALT > 40 U/l in men and > 
31 U/l in women, or AST > 37 U/l in men and > 31 U/l in women7. Controls were those 
without any evidence of metabolic abnormalities.
Ultrasonographic data
The ultrasound examinations were performed in subjects who were 20 to 74 years old using 
Toshiba Sonolayer SSA-90A and Toshiba video recorder during the study period from 1988 
to 1994. The gallbladder ultrasound examinations were performed using standardized 
procedures to ensure consistency, reliability, and accurate results10. During 2009–2010, 
these archived gallbladder ultrasound video images were re-reviewed for assessment and 
grading of hepatic steatosis. Three ultrasound readers were trained by a board certified 
radiologist (specialized in hepatic imaging) for assessment of hepatic steatosis using 
standardized reading protocols. For quality assurance and quality control, a radiologist with 
21 years of experience in the interpretation of ultrasound images validated the readers 
throughout the study period. The liver was graded as normal, mild, moderate, or severe 
hepatic steatosis based on following information: 1) the presence of liver-to-kidney contrast, 
2) the degree of the brightness of liver parenchyma, 3) presence of deep beam attenuation, 4) 
presence of echogenic walls in the small intrahepatic vessels, and 5) the definition of the 
gallbladder walls. Further details regarding ultrasound examinations are provided in the 
supplementary data and are described elsewhere10. According to the NHANES manual, the 
inter-rater reliability between readers for four levels grading (normal, mild, moderate and 
severe) of hepatic steatosis had only 75% agreement (kappa 0.58). While inter-rater 
reliability between readers for recoded dichotomous hepatic steatosis (normal/mild and 
moderate/severe) had 88.7% agreement (kappa 0.70). Further, the NHANES ultrasound user 
analytic manual also recommended users to use recoded dichotomous variable for 
assessment of hepatic steatosis for analyses3. Based on this reason and the studies by 
others11–13, only those subjects with the ultrasonographic findings of moderate or severe 
hepatic steatosis were considered to have NAFLD in our study.
NAFLD Fibrosis Score
For prediction of advanced fibrosis in individuals with NAFLD, we used the NAFLD 
Fibrosis Score which is based on age, BMI, impaired fasting glucose or diabetes, platelet 
count, albumin, and aspartate aminotransferase and alanine aminotransferase ratio6. The 
score of >0.676 was considered as advanced fibrosis while that of < −1.455 were considered 
to have no advanced fibrosis. Score of −1.455 to 0.676 was considered as indeterminate.
Statistical analysis
The prevalence of NAFLD was estimated for overall study cohort, and for those with or 
without metabolic syndrome. The prevalence were weighted to represent the total United 
States population estimates and to account for unequal selection probabilities from the study 
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design and complexity of survey data. Basic descriptive statistics for study population were 
described using both un-weighted frequencies and weighted percentage. They were reported 
as mean, standard deviations, and respective 95% confidence interval.
Individuals with metabolic abnormalities were compared to controls using appropriate 
comparison tests including chi-square test and student t-test accounted for the sample 
weights. Forward stepwise logistic regression method was used to identify independent 
predictors of NAFLD. Variables with p value <0.05 were considered significant and were 
added in the final logistic model. The associations were reported as adjusted odds ratios 
(adjusted for age, sex, race, smoking, alcohol use, and education level). Comparison of an 
individual metabolic abnormality with controls using multivariate model was further 
adjusted for other metabolic abnormalities to control for the confounding effects on hepatic 
steatosis. All analyses were performed using SAS 9.3 (SAS Institute, Cary, North Carolina, 
USA).
RESULTS
Baseline characteristics of study participants (n=11,674) showed mean age of 42.1 years, 
46.2% male, 76% non-Hispanic White and 28.4% current smokers. The details demographic 
and baseline characteristics are provided in table 1.
Prevalence and demographic predictors of NAFLD diagnosed in the US population
The prevalence of NAFLD among US population was 18.2% (95% CI 16.5% – 19.9%). 
Older individuals (60 to 74 years), males, Mexican Americans, and those with lower 
education were found to have higher prevalence of NAFLD (Table 1). Multivariate analysis 
confirmed the following baseline characteristics to be independent predictors of NAFLD; 
male: adjusted odds ratio (aOR) =1.52 [95% CI 1.32 – 1.75]; Mexican American compared 
to non-Hispanic white: aOR=1.62 [95% CI 1.27–2.06]; and less than high school education: 
aOR=1.51 [95% CI 1.25 – 1.82].
Prevalence of metabolic syndrome (MetS) in the US population
The prevalence of MetS in our cohort was 21% (1,715 with three metabolic abnormalities 
[MetS3], 862 with four [MetS4], and 240 with five abnormalities [MetS5]). The detailed 
characteristics of individuals with metabolic abnormalities compared to controls are outlined 
in Table 2.
Levels of transaminases and NAFLD fibrosis scores among subjects with NAFLD
Only 15% of subjects with NAFLD had elevated serum transaminases using the reference 
cut-off. The NAFLD Fibrosis score was calculated among 1,468 with moderate to severe 
steatosis from the ultrasonography. Of these, 6.6% had advanced fibrosis, 60% had no 
fibrosis, and 33.6% were in indeterminate range. We also performed a separate analyses for 
NAFLD fibrosis score by including individuals with mild steatosis. The results are shown in 
supplementary Table 1.
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Prevalence of NAFLD in individuals with metabolic syndrome
The prevalence of NAFLD among individuals with metabolic syndrome (n=2,817) was 43% 
and significantly higher than controls without metabolic syndrome [aOR 11.5, 95% CI 8.9–
14.7, Table 3]. Of these, 24% had moderate steatosis; while 19% had severe steatosis. 
Twenty percent of NAFLD subjects with metabolic syndrome had elevated transaminases. 
Further, we found that the prevalence of NAFLD among subjects with MetS increased with 
the number of metabolic abnormalities (37%, 49% and 67% for those with MetS3, MetS4, 
and MetS5, respectively, Table 3). The prevalence of severe steatosis was also increased with 
higher metabolic abnormalities; 16%, 20% and 35% for subjects with MetS3, MetS4, and 
MetS5 (p <0.001, Figure 1). Among patients with metabolic syndrome, 11% already had 
advanced fibrosis at the time of NAFLD diagnosis (Table 4). When compared to controls, 
NAFLD subjects with metabolic syndrome were older (51.0 vs. 35.6 years, p<0.001) and 
had lower education (31.0% vs. 15.1%, p<0.001). There was no gender and racial difference 
between both groups (Table 2).
Prevalence of NAFLD based on the individual component of metabolic syndrome in the US 
population
NAFLD in individuals with increased waist circumference—The prevalence of 
NAFLD in subjects with increased waist circumference was 31% and it was significantly 
higher than that in controls with normal waist circumference (6%, p < 0.001, Table 3). Of 
these, 17% had elevated serum transaminases, and 8.7% had advanced fibrosis (Tables 3 and 
4). In comparison to controls, NAFLD individuals with increased waist circumference were 
older (47.1 vs. 35.6 years, p<0.001), predominantly female (64.1% vs. 53.8%, p<0.001) and 
less educated (27.1% vs. 15.1%, p<0.001, Table 2).
NAFLD in individuals with impaired fasting glucose / diabetes—The prevalence 
of NAFLD in subjects with impaired fasting glucose/diabetes was 41% and is significantly 
higher than that of controls (6%, p = 0.007, Table 3). Of these, 20% had elevated serum 
transaminases, and 18% had advanced fibrosis (Tables 3 and 4). In comparison to controls, 
NAFLD subjects with impaired fasting glucose were older (53.7 vs. 35.6 years, p<0.001) 
and had lower education (34.9% vs. 15.1%, p<0.001). However, both groups did not differ 
significantly with regards to sex, race, smoking or alcohol use (Table 2).
NAFLD in individuals with high triglyceride and low HDL levels—The prevalence 
of NAFLD in subjects with high triglyceride and low HDL level was 35% and 28% 
respectively. However, the prevalence of advanced fibrosis in those with high triglyceraide 
and low HDL was identical (8%, Table 3 and 4). Both conditions were independent 
predictors of NAFLD after adjusting for other metabolic abnormalities (high triglyceride 
[aOR: 2.2, 95% CI 1.5 – 3.0] and low HDL [aOR: 1.5, 95% CI 1.2 – 1.9, Table 3].
NAFLD in individuals with high blood pressure—The prevalence of NAFLD in 
subjects with high blood pressure was 29%. Of these, 18% had elevated serum 
transaminases, and 11% had advanced fibrosis (Tables 3 and 4). Despite the high prevalence 
of NAFLD among subjects with high blood pressure compared to controls (29% vs. 6%), 
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high blood pressure was not an independent predictor of NAFLD [aOR: 1.3, 95% CI 0.9 – 
1.8, Table 3] in the multivariate analysis.
Prevalence of NAFLD in US population without metabolic abnormalities
The prevalence of NAFLD in the absence of the metabolic syndrome and any of its 
individual components was 6%. Of these, 5% and 1.5% had moderate and severe steatosis, 
respectively. The detailed demographics of these subjects are provided in Table 5. In the 
multivariate model, only Mexican American race (compared to non-Hispanic white) was 
found to be an independent predictor for NAFLD in subjects without any components of 
metabolic abnormalities [aOR: 2.1, 95% CI 1.3 – 3.4].
DISCUSSION
We and others have reported the high occurrence of NAFLD among subjects with metabolic 
syndrome4, 14. In this study, we provide several novel findings with clinical relevance 
regarding the association between metabolic syndrome and its individual component and the 
presence of NAFLD using the ultrasonography and its severity as measured by NAFLD 
Fibrosis Score. Several pertinent findings in our study are (i) the prevalence of NAFLD 
among subjects with metabolic syndrome increased with the number of metabolic 
abnormalities and it exceeds 65% in those with all five abnormalities, (ii) subjects with 
higher numbers of metabolic abnormalities tend to have higher prevalence of advanced 
fibrosis at the time of NAFLD diagnosis, (iii) several individual components of metabolic 
syndrome, notably, increased waist circumference, impaired fasting glucose and 
dyslipidemia, are independent predictors of NAFLD, and (iv) NAFLD is also prevalent 
among subjects without any metabolic abnormalities especially in those with Mexican 
American descent.
Current NAFLD guidelines recommend the use of the NAFLD Fibrosis Score and the 
presence of metabolic syndrome to identify individuals who might benefit from liver 
biopsy1. Our study provided the objective evidence in support of this recommendation. We 
observed a significantly higher risk of NAFLD among individuals with metabolic syndrome 
[aOR: 11.5, 95% CI 8.9–14.7, Table 3]. The prevalence of NAFLD and the presence of 
advanced fibrosis increased substantially with the increase in the number of metabolic 
abnormalities (Figure 1, Tables 3 and 4). Our results suggest the possibilities of the 
synergistic effects of different metabolic abnormalities on the pathogenesis and the 
progression of NAFLD.
Our results attest the notion that the levels of serum transaminases should not be used as the 
screening tests for the presence of underlying NAFLD in those who are at risk. Only 
15%-20% of subjects with NAFLD had abnormal transaminases in our study. We suggest 
that the presence of any metabolic abnormalities should prompt the healthcare providers to 
further investigate the possibilities of NAFLD in these subjects, despite serum transaminases 
are within the normal range.
Apart from metabolic abnormalities, we also found age, sex, and race as independent 
predictors of NAFLD. Others have reported the gender and racial differences in patients with 
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NAFLD1. We found the higher prevalence of NAFLD in Mexican Americans compared to 
non-Hispanic white. Interestingly, Mexican Americans descent is the only factor 
independently associated with NAFLD among subjects without metabolic abnormalities 
(Table 5). It is plausible that underlying genetic variation plays an important role for the 
racial differences in NAFLD susceptibility. This notion is supported by the recent discovery 
of the I148M polymorphism of Patatin-like phospholipase domain-containing 3 (PNPLA3), 
which influences hepatic triglycerides accumulation and the susceptibility to fibrosis. This 
allele is found to be most prevalent in Hispanic compared to other ethnicities2, 15, 16.
It is well known that NAFLD is part of the spectrum of the metabolic syndrome1, 14. 
However, our study reveals that the risk on NAFLD, in fact, in increased in subjects who 
have abnormalities in any components of metabolic abnormalities, except for high blood 
pressure (Figure 2 and Table 3). Hepatic steatosis was found in 41% of subjects with 
impaired fasting glucose or diabetes and at the time of the diagnosis ~18% already had 
advanced fibrosis, based on NAFLD fibrosis scores. Our findings are of importance as the 
prevalence of metabolic abnormalities has increased dramatically in the US since NHANES 
III was conducted. Undoubtedly, this might have led to an even higher prevalence of 
NAFLD in the US population than that reported using NHANES III. Current practice 
guidelines suggested that liver biopsy should be performed among suspected NAFLD with 
metabolic syndrome and those with advanced fibrosis by NAFLD Fibrosis Score. This may 
lead to ~10% of US population between ages 20 to 74 years old requiring liver biopsy based 
on our study results. This number might be significantly higher as the prevalence of 
metabolic syndrome has increased from ~28% in 1988–1994 to ~34% in 1999–200617. 
Undeniably, this will have significant financial impact on the healthcare system. Considering 
significantly high risk of NAFLD and advanced fibrosis among subjects with any metabolic 
abnormalities, future studies to determine the cost effectiveness of noninvasive methods for 
identifying NAFLD among these subjects are warranted.
We acknowledge several limitations of our study. First, NHANES III database do not 
provide histological data which limited us to further categorize NAFLD by histological 
subtypes and evaluating its association with metabolic abnormalities. Second, our results 
might not be applicable to specific populations such as homeless, institutionalized, and 
incarcerated individuals; which were not part of the NHANES survey. Third, we may not be 
able to exclude rare hereditary syndromes which account for small fraction of individuals 
with hepatic steatosis due to the unavailability of dataset. Fourth, some degree of recall bias 
may have been present while evaluating for alcohol consumption or medication use from 
NHANES III questionnaire. Fifth, the reported sensitivity of NAFLD Fibrosis Score to 
predict fibrosis is around 67%. Therefore, we in fact might under estimate the true 
prevalence of advanced fibrosis among NAFLD subjects in our study. Sixth, the ultrasound 
is not the most sensitive method to characterize steatosis or diagnose NAFLD but it is the 
most practical test for large population based study when obtaining liver biosy in these 
subjects is not feasible. Lastly, it is important to note that the inter-rater reliability for four 
level steatosis grading had Kappa of 0.58 which is considered as weak reliability10. This 
may affect our ability to accurately estimate fibrosis in various groups.
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In conclusion, our study suggests significantly high prevalence of NAFLD among 
individuals with the metabolic syndrome and its individual components in the US 
population. Further well designed, prospective, long term, outcome-based studies among 
these high risk groups will provide further insight on the disease process and will definitely 
aid in clinical care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Number of metabolic abnormalities and severity of hepatic steatosis
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Figure 2. 
Severity of hepatic steatosis in metabolic abnormalities and controls
Abbreviations: MetS – metabolic syndrome, WC – waist circumference, IFG – impaired 
fasting glucose, DM – diabetes, HDL – high density lipoprotein, BP – blood pressure
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Table 1
Baseline characteristics of study cohort and prevalence of NAFLD
Characteristic Frequency†
(Weighted %, S.E.)
Prevalence of NAFLD
% (95% CI)
All subjects 11,674 (100%, 0.0) 18.2 (16.5 – 19.9)
Age (years, mean) 11,674 (42.1, 0.4) -
Age groups
   20 to 39 years 5520 (49.5%, 1.0) 13.1 (11.1 – 15.0)
   40 to 59 years 3489 (33.3%, 0.7) 21.8 (19.2 – 24.4)
   60 to 74 years 2665 (17.2%, 0.8) 25.7 (23.3 – 28.1)
Sex
   Male 5203 (46.2%, 0.5) 21.2 (19.0 – 23.4)
   Female 6471 (53.8%, 0.5) 15.6 (13.8 – 17.4)
Race
   Non-Hispanic white 4278 (75.6%, 1.2) 18.0 (16.1 – 19.9)
   Non-Hispanic black 3510 (11.1%, 0.7) 15.4 (12.9 – 17.9)
   Mexican-American 3400 (5.4%, 0.5) 25.7 (21.2 – 30.2)
   Other 486 (7.9%, 0.8) 18.4 (13.0 – 23.8)
Education
   Less than high school 4370 (22.4%, 1.0) 23.3 (20.6 – 25.9)
   High school 3692 (34.4%, 0.8) 18.9 (16.4 – 21.4)
   More than high school 3536 (43.1%, 1.3) 15.0 (13.1 – 17.0)
Marital status
   Married 7423 (67.9%, 0.9) 19.1 (17.3 – 21.0)
   Widowed, divorced, separated, never married 4224 (32.1%, 0.9) 16.1 (14.0 – 18.2)
Poverty index
   Below poverty level 2464 (12.1%, 0.8) 20.4 (17.6 – 23.2)
   At or above poverty level 8160 (87.9%, 0.8) 17.9 (16.1 – 19.7)
Current smoker
   Yes 3138 (28.4%, 0.9) 15.5 (13.1 – 18.0)
   No 8535 (71.6%, 0.9) 19.2 (17.5 – 20.9)
Alcohol use (drinks/day, mean) 11,674 (0.34, 0.01) -
Body mass index
   ≤ 24.9 4619 (45.9%, 1.0) 7.7 (6.3 – 9.2)
   25–29.9 4045 (32.6%, 0.6) 19.9 (17.9 – 22.0)
   ≥30 2987 (21.5%, 0.8) 37.7 (34.2 – 41.2)
†
The total vary according to availability of data
Abbreviations: S.E. – standard error, CI – confidence interval
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Table 3
NAFLD among individuals with metabolic abnormalities
Prevalence of
NAFLD
% (95% CI)
Percentage of NAFLD
with elevated liver enzymes
Hepatic steatosis compared to controls
aOR* (95% CI) p value
Metabolic syndrome 43.2 (39.4 – 46.9) 19.9% (1.9) 11.5 (8.9 – 14.7) <0.001
   Three abnormalities 37.3 (33.7 – 41.0) 18.1% (2.4) 9.7 (7.6 – 12.5) <0.001
   Four abnormalities 48.5 (43.9 – 53.1) 21.6% (3.8) 16.9 (12.0 – 23.8) <0.001
   Five abnormalities 67.3 (56.7 – 77.8) 22.8% (4.5) 37.6 (25.0 – 56.3) <0.001
Increased WC† 31.2 (28.6 – 33.9) 17.1% (1.6) 2.9 (2.2 – 3.8) <0.001
IFG/Diabetes† 41.2 (36.6 – 45.9) 20.3% (2.8) 2.0 (1.2 – 3.4) 0.007
High Triglyceride level† 34.7 (31.8 – 37.6) 19.0% (2.1) 2.2 (1.5 – 3.0) <0.001
Low HDL level† 27.8 (25.1 – 30.4) 17.6% (2.0) 1.5 (1.2 – 1.9) <0.001
High BP† 29.2 (26.5 – 31.9) 17.9% (1.9) 1.3 (0.9 – 1.8) 0.060
Abbreviations: NAFLD – nonalcoholic fatty liver disease, WC – waist circumference, IFG – impaired fasting glucose, HDL – high density 
lipoprotein,
*
aOR – adjusted odds ratio (adjusted for age, sex, race, smoking, alcohol use, and education level), CI – confidence interval, S.E. – standard error 
of percentage
†Odds ratio further adjusted for other metabolic abnormalities
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Table 4
Advanced fibrosis among NAFLD individuals with metabolic abnormalities€
Moderate or severe hepatic steatosis
individuals
Percentage with advanced fibrosis
% (S.E.)
No Indeterminate Yes
All (n = 1468) 59.8% (2.1) 33.6% (1.8) 6.6% (0.9)
Metabolic syndrome (n = 804) 43.0% (3.5) 45.9% (3.2) 11.1% (1.7)
   Three abnormalities (n = 373) 52.4% (4.4) 40.8% (4.4) 6.8% (2.2)
   Four abnormalities (n = 287) 43.5% (5.3) 49.3% (5.2) 7.2% (1.7)
   Five abnormalities (n = 144) 17.6% (5.1) 52.1% (4.9) 30.3% (4.5)
Increased WC (n = 1038) 49.9% (2.6) 41.5% (2.2) 8.7% (1.3)
IFG/Diabetes (n = 556) 27.7% (3.8) 53.7% (3.4) 18.6% (2.8)
High Triglyceride level (n = 752) 54.2% (3.8) 38.0% (3.4) 7.7% (1.1)
Low HDL level (n = 767) 54.8% (3.0) 37.2% (2.7) 8.0% (1.1)
High BP (n = 713) 44.8% (2.9) 44.3% (2.8) 10.9% (1.7)
Abbreviations: NAFLD – nonalcoholic fatty liver disease, WC – waist circumference, IFG – impaired fasting glucose, S.E. – standard error of 
percentage
€
not included if missing value for age, body mass index, impaired fasting glucose/diabetes, platelet count, albumin, aspartate aminotransferase, or 
alanine aminotransferase
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Table 5
Prevalence of NAFLD among individuals without metabolic abnormalities
Characteristic Prevalence of NAFLD
% (95% CI)
All subjects (n=3075) 6.1 (5.0 – 7.1)
Age groups
  20 to 39 years 6.2 (4.8 – 7.6)
  40 to 59 years 6.3 (4.5 – 8.2)
  60 to 74 years 3.6 (1.1 – 6.1)
Sex
  Male 5.6 (4.0 – 7.1)
  Female 6.5 (4.8 – 8.2)
Race
  Non-Hispanic white 5.3 (4.0 – 6.6)
  Non-Hispanic black 8.9 (6.4 – 11.4)
  Mexican-American 10.5 (6.7 – 14.2)
  Other 7.0 (1.0 – 13.1)
Education
  Less than high school 6.9 (4.7 – 9.1)
  High school 5.7 (3.9 – 7.5)
  More than high school 6.1 (4.7 – 7.6)
Poverty index
  Below poverty level 6.4 (3.3 – 9.5)
  At or above poverty level 6.0 (4.8 – 7.3)
Current smoker
  Yes 7.1 (5.0 – 9.1)
  No 5.7 (4.4 – 7.1)
Country of birth
  United States 6.1 (4.9 – 7.3)
  Mexico 11.0 (6.0 – 16.0)
  other 3.8 (0.6 – 7.0)
Abbreviations: NAFLD – nonalcoholic fatty liver disease, CI – confidence interval
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